Donor simvastatin treatment prevents ischemia-reperfusion and acute kidney injury by preserving microvascular barrier function

American Journal of Transplantation

Volumn 13, Issue 8, 2013, Pages 2019-2034

  Tuuminen, R ^a,b   Nykanen A I ^a   Saharinen, P ^c   Gautam, P ^c   Keranen M A I ^a   Arnaudova, R ^a   Rouvinen, E ^a   Helin, H ^d   Tammi, R ^b   Rilla, K ^b   Krebs, R ^a   Lemstrom K B ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b UNIVERSITY OF EASTERN FINLAND   (Finland)

^c UNIVERSITY OF HELSINKI   (Finland)

^d HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Donor; ischemia reperfusion injury; kidney allograft; simvastatin; transplantation

Indexed keywords

ANGIOPOIETIN 2; CHOLESTEROL; CREATININE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ENDOTHELIN 1; KRUPPEL LIKE FACTOR 2; SIMVASTATIN;

ACUTE KIDNEY FAILURE; ADAPTIVE IMMUNITY; ANIMAL EXPERIMENT; ARTERY CLAMP; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; EXOCYTOSIS; IMMUNOREACTIVITY; ISCHEMIA; KIDNEY ALLOGRAFT; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REPERFUSION INJURY; SINGLE DRUG DOSE; TUBULAR DYSFUNCTION; WEIBEL PALADE BODY;

DONOR; ISCHEMIA-REPERFUSION-INJURY; KIDNEY ALLOGRAFT; SIMVASTATIN; TRANSPLANTATION;

ACUTE KIDNEY INJURY; ANIMALS; GRAFT SURVIVAL; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IMMUNITY, INNATE; KIDNEY; KIDNEY TRANSPLANTATION; MALE; MICROVESSELS; RATS; RATS, INBRED WF; REPERFUSION INJURY; SIMVASTATIN;

EID: 84881376100     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.12315     Document Type: Article

References (62)

1. Axelrod DA, McCullough KP, Brewer ED, Becker BN, Segev DL, Rao PS., Kidney and pancreas transplantation in the United States, 1999-2008: The changing face of living donation. Am J Transplant 10 (4 Pt 2): 987-1002.
2. Webb L, Casula A, Ravanan R, Tomson CR., UK Renal Registry 12th Annual Report (December 2009): Chapter 5: Demographic and biochemistry profile of kidney transplant recipients in the UK in 2008: National and centre-specific analyses. Nephron Clin Pract 115 (Suppl 1): c69-c102.
3. Dragun D, Hoff U, Park JK, et al. Prolonged cold preservation augments vascular injury independent of renal transplant immunogenicity and function. Kidney Int 2001; 60 (3): 1173-1181.
4. Ojo AO, Wolfe RA, Held PJ, Port FK, Schmouder RL., Delayed graft function: Risk factors and implications for renal allograft survival. Transplantation 1997; 63 (7): 968-974.
5. Salahudeen AK, Haider N, May W., Cold ischemia and the reduced long-term survival of cadaveric renal allografts. Kidney Int 2004; 65 (2): 713-718.
6. Molitoris BA, Dagher PC, Sandoval RM, et al. siRNA targeted to p53 attenuates ischemic and cisplatin-induced acute kidney injury. J Am Soc Nephrol 2009; 20 (8): 1754-1764.
7. Kwon O, Hong SM, Sutton TA, Temm CJ., Preservation of peritubular capillary endothelial integrity and increasing pericytes may be critical to recovery from postischemic acute kidney injury. Am J Physiol Renal Physiol 2008; 295 (2): F351-F359.
8. Molitoris BA., Actin cytoskeleton in ischemic acute renal failure. Kidney Int 2004; 66 (2): 871-883.
9. Yemisci M, Gursoy-Ozdemir Y, Vural A, Can A, Topalkara K, Dalkara T., Pericyte contraction induced by oxidative-nitrative stress impairs capillary reflow despite successful opening of an occluded cerebral artery. Nat Med 2009; 15 (9): 1031-1037.
10. Dekker RJ, van Soest S, Fontijn RD, et al. Prolonged fluid shear stress induces a distinct set of endothelial cell genes, most specifically lung Kruppel-like factor (KLF2). Blood 2002; 100 (5): 1689-1698.
11. Lin Z, Kumar A, SenBanerjee S, et al. Kruppel-like factor 2 (KLF2) regulates endothelial thrombotic function. Circ Res 2005; 96 (5): e48-e57.
12. Kawachi S, Hines IN, Laroux FS, et al. Nitric oxide synthase and postischemic liver injury. Biochem Biophys Res Commun 2000; 276 (3): 851-854.
13. Kawashima S, Yamashita T, Ozaki M, et al. Endothelial NO synthase overexpression inhibits lesion formation in mouse model of vascular remodeling. Arterioscler Thromb Vasc Biol 2001; 21 (2): 201-207.
14. Xuan YT, Guo Y, Zhu Y, Wang OL, Rokosh G, Bolli R., Endothelial nitric oxide synthase plays an obligatory role in the late phase of ischemic preconditioning by activating the protein kinase C epsilon p44/42 mitogen-activated protein kinase pSer-signal transducers and activators of transcription1/3 pathway. Circulation 2007; 116 (5): 535-544.
15. Blydt-Hansen TD, Katori M, Lassman C, et al. Gene transfer-induced local heme oxygenase-1 overexpression protects rat kidney transplants from ischemia/reperfusion injury. J Am Soc Nephrol 2003; 14 (3): 745-754.
16. Gueler F, Park JK, Rong S, et al. Statins attenuate ischemia-reperfusion injury by inducing heme oxygenase-1 in infiltrating macrophages. Am J Pathol 2007; 170 (4): 1192-1199.
17. Holzen JP, August C, Bahde R, et al. Influence of heme oxygenase-1 on microcirculation after kidney transplantation. J Surg Res 2008; 148 (2): 126-135.
18. Kitazawa T, Masuo M, Somlyo AP., G protein-mediated inhibition of myosin light-chain phosphatase in vascular smooth muscle. Proc Natl Acad Sci USA 1991; 88 (20): 9307-9310.
19. Wojciak-Stothard B, Tsang LY, Haworth SG., Rac and Rho play opposing roles in the regulation of hypoxia/reoxygenation-induced permeability changes in pulmonary artery endothelial cells. Am J Physiol Lung Cell Mol Physiol 2005; 288 (4): L749-L760.
20. Scharpfenecker M, Fiedler U, Reiss Y, Augustin HG., The Tie-2 ligand angiopoietin-2 destabilizes quiescent endothelium through an internal autocrine loop mechanism. J Cell Sci 2005; 118 (Pt 4): 771-780.
21. Gurbanov K, Rubinstein I, Hoffman A, Abassi Z, Better OS, Winaver J., Differential regulation of renal regional blood flow by endothelin-1. Am J Physiol 1996; 271 (6 Pt 2): F1166-F1172.
22. Vischer UM, Barth H, Wollheim CB., Regulated von Willebrand factor secretion is associated with agonist-specific patterns of cytoskeletal remodeling in cultured endothelial cells. Arterioscler Thromb Vasc Biol 2000; 20 (3): 883-891.
23. Rondaij MG, Bierings R, Kragt A, van Mourik JA, Voorberg J., Dynamics and plasticity of Weibel-Palade bodies in endothelial cells. Arterioscler Thromb Vasc Biol 2006; 26 (5): 1002-1007.
24. Weitz-Schmidt G, Welzenbach K, Brinkmann V, et al. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat Med 2001; 7 (6): 687-692.
25. Rezaie-Majd A, Maca T, Bucek RA, et al. Simvastatin reduces expression of cytokines interleukin-6, interleukin-8, and monocyte chemoattractant protein-1 in circulating monocytes from hypercholesterolemic patients. Arterioscler Thromb Vasc Biol 2002; 22 (7): 1194-1199.
26. Shimizu K, Aikawa M, Takayama K, Libby P, Mitchell RN., Direct anti-inflammatory mechanisms contribute to attenuation of experimental allograft arteriosclerosis by statins. Circulation 2003; 108 (17): 2113-2120.
27. Yilmaz A, Reiss C, Tantawi O, et al. HMG-CoA reductase inhibitors suppress maturation of human dendritic cells: New implications for atherosclerosis. Atherosclerosis 2004; 172 (1): 85-93.
28. Niessner A, Steiner S, Speidl WS, et al. Simvastatin suppresses endotoxin-induced upregulation of toll-like receptors 4 and 2 in vivo. Atherosclerosis 2006; 189 (2): 408-413.
29. Wagner AH, Kohler T, Ruckschloss U, Just I, Hecker M., Improvement of nitric oxide-dependent vasodilatation by HMG-CoA reductase inhibitors through attenuation of endothelial superoxide anion formation. Arterioscler Thromb Vasc Biol 2000; 20 (1): 61-69.
30. Lee TS, Chang CC, Zhu Y, Shyy JY., Simvastatin induces heme oxygenase-1: A novel mechanism of vessel protection. Circulation 2004; 110 (10): 1296-1302.
31. Joyce M, Kelly C, Winter D, Chen G, Leahy A, Bouchier-Hayes D., Pravastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, attenuates renal injury in an experimental model of ischemia-reperfusion. J Surg Res 2001; 101 (1): 79-84.
32. Lefer AM, Campbell B, Shin YK, Scalia R, Hayward R, Lefer DJ., Simvastatin preserves the ischemic-reperfused myocardium in normocholesterolemic rat hearts. Circulation 1999; 100 (2): 178-184.
33. Di Napoli P, Antonio Taccardi A, Grilli A, et al. Simvastatin reduces reperfusion injury by modulating nitric oxide synthase expression: An ex vivo study in isolated working rat hearts. Cardiovasc Res 2001; 51 (2): 283-293.
34. Welten GM, Chonchol M, Schouten O, et al. Statin use is associated with early recovery of kidney injury after vascular surgery and improved long-term outcome. Nephrol Dial Transplant 2008; 23 (12): 3867-3873.
35. Molnar AO, Coca SG, Devereaux PJ, et al. Statin use associates with a lower incidence of acute kidney injury after major elective surgery. J Am Soc Nephrol 22 (5): 939-946.
36. Tuuminen R, Syrjala S, Krebs R, et al. Donor simvastatin treatment abolishes rat cardiac allograft ischemia/reperfusion injury and chronic rejection through microvascular protection. Circulation 124 (10): 1138-1150.
37. Salman IM, Sattar MA, Abdullah NA, et al. Renal ischemic injury affects renal hemodynamics and excretory functions in Sprague Dawley rats: Involvement of renal sympathetic tone. Ren Fail 32 (1): 96-102.
38. Kimura K, Ito M, Amano M, et al. Regulation of myosin phosphatase by Rho and Rho-associated kinase (Rho-kinase). Science 1996; 273 (5272): 245-248.
39. Fukata Y, Oshiro N, Kinoshita N, et al. Phosphorylation of adducin by Rho-kinase plays a crucial role in cell motility. J Cell Biol 1999; 145 (2): 347-361.
40. Goransson V, Johnsson C, Jacobson A, Heldin P, Hallgren R, Hansell P., Renal hyaluronan accumulation and hyaluronan synthase expression after ischaemia-reperfusion injury in the rat. Nephrol Dial Transplant 2004; 19 (4): 823-830.
41. Lin Z, Natesan V, Shi H, et al. Kruppel-like factor 2 regulates endothelial barrier function. Arterioscler Thromb Vasc Biol 30 (10): 1952-1959.
42. SenBanerjee S, Lin Z, Atkins GB, et al. KLF2 Is a novel transcriptional regulator of endothelial proinflammatory activation. J Exp Med 2004; 199 (10): 1305-1315.
43. Parmar KM, Nambudiri V, Dai G, Larman HB, Gimbrone MA, Jr., Garcia-Cardena G., Statins exert endothelial atheroprotective effects via the KLF2 transcription factor. J Biol Chem 2005; 280 (29): 26714-26719.
44. SenBanerjee S, Mir S, Lin Z, et al. Kruppel-like factor 2 as a novel mediator of statin effects in endothelial cells. Circulation 2005; 112 (5): 720-726.
45. Ali F, Hamdulay SS, Kinderlerer AR, et al. Statin-mediated cytoprotection of human vascular endothelial cells: A role for Kruppel-like factor 2-dependent induction of heme oxygenase-1. J Thromb Haemost 2007; 5 (12): 2537-2546.
46. Pinsky DJ, Naka Y, Liao H, et al. Hypoxia-induced exocytosis of endothelial cell Weibel-Palade bodies. A mechanism for rapid neutrophil recruitment after cardiac preservation. J Clin Invest 1996; 97 (2): 493-500.
47. Goligorsky MS, Patschan D, Kuo MC., Weibel-Palade bodies-Sentinels of acute stress. Nat Rev Nephrol 2009; 5 (7): 423-426.
48. David S, John SG, Jefferies HJ, et al. Angiopoietin-2 levels predict mortality in CKD patients. Nephrol Dial Transplant. 2012; 27 (5): 1867-1872.
49. Eitel I, Nowak M, Stehl C, et al. Endothelin-1 release in acute myocardial infarction as a predictor of long-term prognosis and no-reflow assessed by contrast-enhanced magnetic resonance imaging. Am Heart J 159 (5): 882-890.
50. Cavarape A, Endlich N, Assaloni R, et al. Rho-kinase inhibition blunts renal vasoconstriction induced by distinct signaling pathways in vivo. J Am Soc Nephrol 2003; 14 (1): 37-45.
51. Brezis M, Rosen S., Hypoxia of the renal medulla-Its implications for disease. N Engl J Med 1995; 332 (10): 647-655.
52. Prasad PV., Evaluation of intra-renal oxygenation by BOLD MRI. Nephron Clin Pract 2006; 103 (2): c58-c65.
53. Kentrup D, Reuter S, Schnockel U, et al. Hydroxyfasudil-mediated inhibition of ROCK1 and ROCK2 improves kidney function in rat renal acute ischemia-reperfusion injury. PLoS ONE 6 (10): e26419.
54. Patel S, Mason RM, Suzuki J, Imaizumi A, Kamimura T, Zhang Z., Inhibitory effect of statins on renal epithelial-to-mesenchymal transition. Am J Nephrol 2006; 26 (4): 381-387.
55. Scheibner KA, Lutz MA, Boodoo S, Fenton MJ, Powell JD, Horton MR., Hyaluronan fragments act as an endogenous danger signal by engaging TLR2. J Immunol 2006; 177 (2): 1272-1281.
56. Webber J, Jenkins RH, Meran S, Phillips A, Steadman R., Modulation of TGFbeta1-dependent myofibroblast differentiation by hyaluronan. Am J Pathol 2009; 175 (1): 148-160.
57. Webber J, Meran S, Steadman R, Phillips A., Hyaluronan orchestrates transforming growth factor-beta1-dependent maintenance of myofibroblast phenotype. J Biol Chem 2009; 284 (14): 9083-9092.
58. Bourguignon LY, Singleton PA, Zhu H, Zhou B., Hyaluronan promotes signaling interaction between CD44 and the transforming growth factor beta receptor I in metastatic breast tumor cells. J Biol Chem 2002; 277 (42): 39703-39712.
59. Navaneethan SD, Perkovic V, Johnson DW, Nigwekar SU, Craig JC, Strippoli GF., HMG CoA reductase inhibitors (statins) for kidney transplant recipients. Cochrane Database Syst Rev 2009; (2): CD005019.
60. Siedlecki A, Irish W, Brennan DC., Delayed graft function in the kidney transplant. Am J Transplant 11 (11): 2279-2296.
61. Gottmann U, Brinkkoetter PT, Hoeger S, et al. Atorvastatin donor pretreatment prevents ischemia/reperfusion injury in renal transplantation in rats: Possible role for aldose-reductase inhibition. Transplantation 2007; 84 (6): 755-762.
62. Hoeger S, Benck U, Petrov K, et al. Atorvastatin donor pre-treatment in a model of brain death and allogeneic kidney transplantation in rat. Ann Transplant 2012; 17 (1): 79-85.